Donidalorsen: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -151% 1 103 Improvement, Studies, Patients Relative Risk Mortality -151% 1 103 Ventilation -81% 1 111 RCTs -151% 1 103 Late -151% 1 103 Donidalorsen for COVID-19 c19early.org December 2025 Favorsdonidalorsen Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASKCOV Zampieri (DB RCT) -151% 2.51 [0.89-7.02] death 12/52 6/51 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Late treatment -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk All studies -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk 1 donidalorsen COVID-19 study c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Effect extraction pre-specified(most serious outcome) Favors donidalorsen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASKCOV Zampieri (DB RCT) -151% 2.51 [0.89-7.02] 12/52 6/51 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Late treatment -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk All studies -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk 1 donidalorsen COVID-19 mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Favors donidalorsen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASKCOV Zampieri (DB RCT) -81% 1.81 [0.84-3.14] 21/56 10/55 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.075 Late treatment -81% 1.81 [0.84-3.14] 21/56 10/55 81% higher risk All studies -81% 1.81 [0.84-3.14] 21/56 10/55 81% higher risk 1 donidalorsen COVID-19 mechanical ventilation result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.075 Favors donidalorsen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASKCOV Zampieri (DB RCT) -151% 2.51 [0.89-7.02] death 12/52 6/51 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Late treatment -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk All studies -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk 1 donidalorsen COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Effect extraction pre-specified(most serious outcome) Favors donidalorsen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASKCOV Zampieri (DB RCT) -151% 2.51 [0.89-7.02] 12/52 6/51 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Late treatment -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk All studies -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk 1 donidalorsen COVID-19 RCT mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Favors donidalorsen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASKCOV Zampieri (DB RCT) -151% 2.51 [0.89-7.02] death 12/52 6/51 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Late treatment -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk All studies -151% 2.51 [0.89-7.02] 12/52 6/51 151% higher risk 1 donidalorsen COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.045 Effect extraction pre-specified(most serious outcome) Favors donidalorsen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ASKCOV Zampieri (DB RCT) -151% 2.51 [0.89-7.02] death 12/52 6/51 Improvement, RR [CI] Treatment Control ASKCOV Zampieri (DB RCT) -82% 1.82 [0.44-5.65] death 9/56 4/55 ASKCOV Zampieri (DB RCT) -81% 1.81 [0.84-3.14] ventilation 21/56 10/55 ASKCOV Zampieri (DB RCT) -35% 1.35 [1.02-1.77] progression 56 (n) 55 (n) Donidalorsen COVID-19 outcomes c19early.org December 2025 Favors donidalorsen Favors control